Intraoperative versus extended antimicrobial prophylaxis after gastric cancer surgery: a phase 3, open-label, randomised controlled, non-inferiority trial

被引:29
|
作者
Imamura, Hiroshi [2 ]
Kurokawa, Yukinori [1 ]
Tsujinaka, Toshimasa [3 ]
Inoue, Kentaro [4 ]
Kimura, Yutaka [5 ]
Iijima, Shohei [6 ]
Shimokawa, Toshio [7 ]
Furukawa, Hiroshi [2 ]
机构
[1] Osaka Univ, Grad Sch Med, Dept Surg Gastroenterol, Suita, Osaka, Japan
[2] Sakai Municipal Hosp, Dept Surg, Osaka, Japan
[3] Osaka Natl Hosp, Dept Surg, Osaka, Japan
[4] Kansai Med Coll, Dept Surg, Osaka, Japan
[5] NTT W Hosp, Dept Surg, Osaka, Japan
[6] Minoh City Hosp, Dept Surg, Osaka, Japan
[7] Univ Yamanashi, Grad Sch Med & Engn, Yamanashi, Japan
来源
LANCET INFECTIOUS DISEASES | 2012年 / 12卷 / 05期
关键词
SURGICAL-SITE INFECTION; ANTIBIOTIC-PROPHYLAXIS; NODAL DISSECTION; RISK-FACTORS; PREVENTION; D2; LYMPHADENECTOMY;
D O I
10.1016/S1473-3099(11)70370-X
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background Although evidence for the efficacy of postoperative antimicrobial prophylaxis is scarce, many patients routinely receive such treatment after major surgeries. We aimed to compare the incidence of surgical-site infections with intraoperative antimicrobial prophylaxis alone versus intraoperative plus postoperative administration. Methods We did a prospective, open-label, phase 3, randomised study at seven hospitals in Japan. Patients with gastric cancer that was potentially curable with a distal gastrectomy were randomly assigned (1:1) to receive either intraoperative antimicrobial prophylaxis alone (cefazolin 1 g before the surgical incision and every 3 h as intraoperative supplements) or extended antimicrobial prophylaxis (intraoperative administration plus cefazolin 1 g once after closure and twice daily for 2 postoperative days). Randomisation was stratified using Pocock and Simon's minimisation method for institution and American Society of Anesthesiologists scores, and Mersenne twister was used for random number generation. The primary endpoint was the incidence of surgical-site infections. We assessed non-inferiority of intraoperative therapy with a margin of 5%. Analysis was by intention-to-treat. During hospital stay, infection-control personnel assessed patients for infection, and the principal surgeons were required to check for surgical-site infections at outpatient clinics until 30 days after surgery. This study is registered with UMIN-CTR, UMIN000000631. Findings Between June 2,2005, and Dec 6,2007,355 patients were randomly assigned to receive either intraoperative antimicrobial prophylaxis alone (n=176) or extended antimicrobial prophylaxis (n=179). Eight patients (5%, 95% CI 2-9%) had surgical-site infections in the intraoperative group compared with 16 (9%, 5-14) in the extended group. The relative risk of surgical-site infections with intraoperative antimicrobial prophylaxis was 0.51 (0.22-1.16), which revealed statistically significant non-inferiority (p<0-0001). Interpretation Elimination of postoperative antimicrobial prophylaxis did not increase the incidence of surgical-site infections after a gastrectomy. Therefore, this treatment is not recommended after gastric cancer surgery. Funding Osaka Gastrointestinal Cancer Chemotherapy Study Group.
引用
收藏
页码:381 / 387
页数:7
相关论文
共 50 条
  • [31] Cryotherapy as prophylaxis against oral mucositis after high-dose melphalan and autologous stem cell transplantation for myeloma: a randomised, open-label, phase 3, non-inferiority trial
    Johansson, Jan-Erik
    Bratel, John
    Hardling, Mats
    Heikki, Lena
    Mellqvist, Ulf-Henrik
    Hasseus, Bengt
    BONE MARROW TRANSPLANTATION, 2019, 54 (09) : 1482 - 1488
  • [32] Preliminary results of hypofractionated radiotherapy in breast cancer in Chandigarh, India: single-centre, non-inferiority, open-label, randomised, phase 3 trial
    Yadav, Budhi Singh
    Dahiya, Divya
    Gupta, Manish
    Gupta, Ankita
    Oinam, Arun S.
    Khare, Siddhant
    Irrinki, Santhosh
    Robert, Ngangom
    Sakaray, Yashwant Raj
    Nagaraj, Satish S.
    Kumari, Reena
    LANCET REGIONAL HEALTH - SOUTHEAST ASIA, 2024, 24
  • [33] Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial
    Takashima, Tsutomu
    Mukai, Hirofumi
    Hara, Fumikata
    Matsubara, Nobuaki
    Saito, Tsuyoshi
    Takano, Toshimi
    Park, Youngjin
    Toyama, Tatsuya
    Hozumi, Yasuo
    Tsurutani, Junji
    Imoto, Shigeru
    Watanabe, Takanori
    Sagara, Yoshiaki
    Nishimura, Reiki
    Shimozuma, Kojiro
    Ohashi, Yasuo
    LANCET ONCOLOGY, 2016, 17 (01): : 90 - 98
  • [34] Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial
    Coles, Charlotte E.
    Haviland, Joanne S.
    Kirby, Anna M.
    Griffin, Clare L.
    Sydenham, Mark A.
    Titley, Jenny C.
    Bhattacharya, Indrani
    Brunt, A. Murray
    Chan, H. Y. Charlie
    Donovan, Ellen M.
    Eaton, David J.
    Emson, Marie
    Hopwood, Penny
    Jefford, Monica L.
    Lightowlers, Sara, V
    Sawyer, Elinor J.
    Syndikus, Isabel
    Tsang, Yat M.
    Twyman, Nicola, I
    Yarnold, John R.
    Bliss, Judith M.
    LANCET, 2023, 401 (10394): : 2124 - 2137
  • [35] Outpatient elective induction of labour at 39 weeks' gestation (HOME INDUCTION): an open-label, randomised, controlled, phase III, non-inferiority trial
    Nicholson, Sarah M.
    Flood, Karen
    Dicker, Patrick
    Molphy, Zara E.
    Smith, Orla T.
    Oprescu, Corina I.
    Wall, Eimear M.
    Nimr, Sara N. El
    Shanahan, Ita M.
    Kennedy, Bernard J.
    V. Daly, Ronan
    Gannon, Geraldine
    Looi, Claudia
    Fernandez, Elena
    Malone, Fergal D.
    ECLINICALMEDICINE, 2024, 74
  • [36] Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial
    Halton, Jacqueline
    Brandao, Leonardo R.
    Luciani, Matteo
    Bomgaars, Lisa
    Chalmers, Elizabeth
    Mitchell, Lesley G.
    Nurmeev, Ildar
    Sharathkumar, Anjali
    Svirin, Pavel
    Gorbatikov, Kirill
    Tartakovsky, Igor
    Simetzberger, Monika
    Huang, Fenglei
    Sun, Zhichao
    Kreuzer, Jorg
    Gropper, Savion
    Reilly, Paul
    Brueckmann, Martina
    Albisetti, Manuela
    LANCET HAEMATOLOGY, 2021, 8 (01): : E22 - E33
  • [37] Subcuticular sutures versus staples for skin closure after open gastrointestinal surgery: a phase 3, multicentre, open-label, randomised controlled trial
    Tsujinaka, Toshimasa
    Yamamoto, Kazuyoshi
    Fujita, Junya
    Endo, Shunji
    Kawada, Junji
    Nakahira, Shin
    Shimokawa, Toshio
    Kobayashi, Shogo
    Yamasaki, Makoto
    Akamaru, Yusuke
    Miyamoto, Atsushi
    Mizushima, Tsunekazu
    Shimizu, Junzo
    Umeshita, Koji
    Ito, Toshinori
    Doki, Yuichiro
    Mori, Masaki
    LANCET, 2013, 382 (9898): : 1105 - 1112
  • [38] Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial
    Cohen, Hannah
    Hunt, Beverley J.
    Efthymiou, Maria
    Arachchillage, Deepa R. J.
    Mackie, Ian J.
    Clawson, Simon
    Sylvestre, Yvonne
    Machin, Samuel J.
    Bertolaccini, Maria L.
    Ruiz-Castellano, Maria
    Muirhead, Nicola
    Dore, Caroline J.
    Khamashta, Munther
    Isenberg, David A.
    Lancet Haematology, 2016, 3 (09): : E426 - E436
  • [39] Appendectomy versus non-operative treatment for acute uncomplicated appendicitis in children: study protocol for a multicentre, open-label, non-inferiority, randomised controlled trial
    Hall, Nigel J.
    Eaton, Simon
    Abbo, Olivier
    Arnaud, Alexis P.
    Beaudin, Marianne
    Brindle, Mary
    Butter, Andreana
    Davies, Dafydd
    Jancelewicz, Tim
    Johnson, Kathy
    Keijzer, Richard
    Lapidus-Krol, Eveline
    Offringa, Martin
    Piche, Nelson
    Rintala, Risto
    Skarsgard, Erik
    Svensson, Jan F.
    Ungar, Wendy J.
    Wester, Tomas
    Willan, Andrew R.
    Zani, Augusto
    St Peter, Shawn D.
    Pierro, Agostino
    BMJ PAEDIATRICS OPEN, 2017, 1 (01)
  • [40] Paclitaxel oral solution versus paclitaxel injection as a second-line therapy in advanced gastric cancer: A randomized, open-label, non-inferiority phase 3 trial.
    Li, Jin
    Huang, Mingzhu
    Deng, Ting
    Bai, Yuxian
    Liu, Tianshu
    Pan, Yueyin
    Yu, Junyan
    Pan, Hongming
    Xu, Huiting
    Wang, Jufeng
    Ye, Feng
    Wang, Junye
    Wu, Jinsheng
    Cang, Shundong
    Chen, Kehe
    Zhang, Jun
    Zhang, Jingdong
    Ling, Yang
    Liu, Yin
    Qin, Shukui
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL)